Oscar Health (OSCR) Q3 2026 Earnings
Revenue included a $250 million benefit from updated risk adjustment estimates; quarter also included $42 million of favorable prior period development.
How Did OSCR Stock React to Q3 2026 Earnings?
Did OSCR Beat Earnings? Q3 2026 Results
Yes. Oscar Health reported Q3 2026 earnings of $0.49 a share on Nov 5, 2026, beating the $-0.17 consensus estimate by 382.6%. Revenue was $5.1B against a $4.7B estimate.
Oscar Health delivered a sharp swing to profitability in the third quarter of 2026, posting GAAP earnings of $0.49 per diluted share against a consensus estimate of negative $0.17, a beat of 382.58%, compared with a loss of $0.53 per share a year earlier. Revenue surged 72.1% year over year to $5.14 billion, clearing the $4.72 billion consensus by 8.93%, driven by rate increases and membership growth that pushed effectuated enrollment to roughly 2.69 million. The quarter's results included a $250 million benefit from updated risk adjustment estimates reflecting favorable risk score development relative to the market, as well as $42 million of favorable prior period development; both items are embedded in the GAAP figures. The medical loss ratio improved to 84.0% from 88.5%, underscoring the pricing discipline management has emphasized all year. Looking ahead, Oscar raised its full-year earnings from operations outlook to $850 million to $950 million, the third increase this year, while lifting its total revenue guidance to $19.0 to $19.3 billion, with management citing plans to expand into additional states and grow market share into 2027.
- Rate increases and higher membership drove revenue to ~$5.1 billion from $3.0 billion
- $250 million revenue benefit from updated risk adjustment estimates due to favorable risk score development and modestly favorable market morbidity
- MLR improved to 84.0% from 88.5%, driven by disciplined pricing
- $42 million favorable prior period development (vs $84 million a year ago)
- SG&A ratio fell to 14.0% from 17.5% on lower risk adjustment as a percentage of premium, fixed cost leverage and expense discipline
- Investment income rose to $91.0 million from $53.2 million
“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time.”
Oscar Health CEO, on the earnings call
What Is Oscar Health's Outlook?
Oscar raised its full-year 2026 outlook. Total revenue is now expected at $19.0–$19.3 billion (prior $18.7–$19.0 billion). Medical loss ratio is expected at 80.5%–81.5% (prior 81.0%–82.0%) and SG&A expense ratio at 15.1%–15.6% (prior 15.6%–16.1%). Earnings from operations are expected at $850–$950 million (prior $600–$800 million), the third raise this year. Management expects to grow market share and expand margin in 2027.
OSCR YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $5.1B | $3.0B | +72.1% |
| Operating Income | $178.0M | $52.7M | +237.7% |
| Net Income | $167.3M | $52.0M | +221.7% |
OSCR Revenue by Segment
When Does Oscar Health Report Next?
Figures from SEC filings and company reports. Not investment advice.